Endoscopic manifestation of intestinal transplant-associated microangiopathy after stem cell transplantation.
Colonoscopy
Esophagogastroduodenoscopy
Graft-versus-host disease
Hematopoietic stem cell transplantation
Intestinal transplant-associated microangiopathy
iTAM
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
22 Apr 2024
22 Apr 2024
Historique:
received:
20
07
2023
accepted:
02
04
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
22
4
2024
Statut:
epublish
Résumé
Endoscopic features of intestinal transplant-associated microangiopathy (iTAM) have not been comprehensively investigated. This study aimed to examine the endoscopic characteristics of patients diagnosed with iTAM. This retrospective analysis included 14 patients pathologically diagnosed with iTAM after stem cell transplantation for hematolymphoid neoplasms (n = 13) or thalassemia (n = 1). The sex, age at diagnosis, endoscopic features, and prognosis of each patient were assessed. Serological markers for diagnosing transplant-associated thrombotic microangiopathy were also evaluated. The mean age at the time of iTAM diagnosis was 40.2 years. Patients diagnosed based on the pathognomonic pathological changes of iTAM presented with diverse symptoms at the times of endoscopic examinations, including diarrhea (n = 10), abdominal pain (n = 5), nausea (n = 4), appetite loss (n = 2), bloody stools (n = 2), abdominal discomfort (n = 1), and vomiting (n = 1). At the final follow-up, six patients survived, while eight patients succumbed, with a median time of 100.5 days (range: 52-247) post-diagnosis. Endoscopic manifestations included erythematous mucosa (n = 14), erosions (n = 13), ulcers (n = 9), mucosal edema (n = 9), granular mucosa (n = 9), and villous atrophy (n = 4). Erosions and/or ulcers were primarily observed in the colon (10/14, 71%), followed by the ileum (9/13, 69%), stomach (4/10, 40%), cecum (5/14, 36%), duodenum (3/10, 30%), rectum (4/14, 29%), and esophagus (1/10, 10%). Cytomegalovirus infection (n = 4) and graft-versus-host disease (n = 2) coexisted within the gastrointestinal tract. Patients had de novo prolonged or progressive thrombocytopenia (6/14, 43%), decreased hemoglobin concentration (4/14, 29%), reduced serum haptoglobin level (3/14, 21%), and a sudden and persistent increase in lactate dehydrogenase level (2/14, 14%). Peripheral blood samples from 12 patients were evaluated for schistocytes, with none exceeding 4%. This study provides a comprehensive exploration of the endoscopic characteristics of iTAM. Notably, all patients exhibited erythematous mucosa throughout the gastrointestinal tract, accompanied by prevalent manifestations, such as erosions (93%), ulcers (64%), mucosal edema (64%), granular mucosa (64%), and villous atrophy (29%). Because of the low positivity for serological markers of transplant-associated thrombotic microangiopathy in patients with iTAM, endoscopic evaluation and biopsy of these lesions are crucial, even in the absence of these serological features.
Sections du résumé
BACKGROUND
BACKGROUND
Endoscopic features of intestinal transplant-associated microangiopathy (iTAM) have not been comprehensively investigated. This study aimed to examine the endoscopic characteristics of patients diagnosed with iTAM.
METHODS
METHODS
This retrospective analysis included 14 patients pathologically diagnosed with iTAM after stem cell transplantation for hematolymphoid neoplasms (n = 13) or thalassemia (n = 1). The sex, age at diagnosis, endoscopic features, and prognosis of each patient were assessed. Serological markers for diagnosing transplant-associated thrombotic microangiopathy were also evaluated.
RESULTS
RESULTS
The mean age at the time of iTAM diagnosis was 40.2 years. Patients diagnosed based on the pathognomonic pathological changes of iTAM presented with diverse symptoms at the times of endoscopic examinations, including diarrhea (n = 10), abdominal pain (n = 5), nausea (n = 4), appetite loss (n = 2), bloody stools (n = 2), abdominal discomfort (n = 1), and vomiting (n = 1). At the final follow-up, six patients survived, while eight patients succumbed, with a median time of 100.5 days (range: 52-247) post-diagnosis. Endoscopic manifestations included erythematous mucosa (n = 14), erosions (n = 13), ulcers (n = 9), mucosal edema (n = 9), granular mucosa (n = 9), and villous atrophy (n = 4). Erosions and/or ulcers were primarily observed in the colon (10/14, 71%), followed by the ileum (9/13, 69%), stomach (4/10, 40%), cecum (5/14, 36%), duodenum (3/10, 30%), rectum (4/14, 29%), and esophagus (1/10, 10%). Cytomegalovirus infection (n = 4) and graft-versus-host disease (n = 2) coexisted within the gastrointestinal tract. Patients had de novo prolonged or progressive thrombocytopenia (6/14, 43%), decreased hemoglobin concentration (4/14, 29%), reduced serum haptoglobin level (3/14, 21%), and a sudden and persistent increase in lactate dehydrogenase level (2/14, 14%). Peripheral blood samples from 12 patients were evaluated for schistocytes, with none exceeding 4%.
CONCLUSIONS
CONCLUSIONS
This study provides a comprehensive exploration of the endoscopic characteristics of iTAM. Notably, all patients exhibited erythematous mucosa throughout the gastrointestinal tract, accompanied by prevalent manifestations, such as erosions (93%), ulcers (64%), mucosal edema (64%), granular mucosa (64%), and villous atrophy (29%). Because of the low positivity for serological markers of transplant-associated thrombotic microangiopathy in patients with iTAM, endoscopic evaluation and biopsy of these lesions are crucial, even in the absence of these serological features.
Identifiants
pubmed: 38649868
doi: 10.1186/s12876-024-03221-y
pii: 10.1186/s12876-024-03221-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
140Informations de copyright
© 2024. The Author(s).
Références
Rosenthal J. Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. J Blood Med. 2016;7:181–6.
doi: 10.2147/JBM.S102235
pubmed: 27621680
pmcid: 5015877
Kim SS, Patel M, Yum K, Keyzner A. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion. 2015;55:452–8.
doi: 10.1111/trf.12859
pubmed: 25209960
Warren M, Jodele S, Dandoy C, Myers KC, Wallace G, Nelson A, et al. A complete histologic approach to gastrointestinal biopsy from hematopoietic stem cell transplant patients with evidence of transplant-associated gastrointestinal thrombotic microangiopathy. Arch Pathol Lab Med. 2017;141:1558–66.
doi: 10.5858/arpa.2016-0599-RA
pubmed: 28795840
El-Bietar J, Warren M, Dandoy C, Myers KC, Lane A, Wallace G, et al. Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21:1994–2001.
doi: 10.1016/j.bbmt.2015.06.016
Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol. 2014;12:565–73.
pubmed: 25654478
Limpert R, Pan P, Wang LS, Chen X. From support to therapy: rethinking the role of nutrition in acute graft-versus-host disease. Front Immunol. 2023;14:1192084.
doi: 10.3389/fimmu.2023.1192084
pubmed: 37359550
pmcid: 10285162
Chakupurakal G, Freudenberger P, Skoetz N, Ahr H, Theurich S. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev. 2023;6:CD009159.
pubmed: 37341189
Fatima A, Haddad SF, Johnny Z, Kanj SS. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants. Int J Antimicrob Agents. 2023;62:106860.
doi: 10.1016/j.ijantimicag.2023.106860
Iwamuro M, Kondo T, Ennishi D, Fujii N, Matsuoka KI, Takahashi T, et al. Feasibility of flow cytometry analysis of gastrointestinal tract-residing lymphocytes in hematopoietic stem cell transplant recipients. Acta Med Okayama. 2023;77:347–57.
pubmed: 37635134
Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95–100.
doi: 10.3324/haematol.10699
pubmed: 17229640
Nishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y, et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transpl. 2004;33:1143–50.
doi: 10.1038/sj.bmt.1704512
Yamada R, Nemoto T, Ohashi K, Tonooka A, Horiguchi SI, Motoi T, et al. Distribution of transplantation-associated thrombotic microangiopathy (TA-TMA) and comparison between renal TA-TMA and intestinal TA-TMA: autopsy study. Biol Blood Marrow Transpl. 2020;26:178–88.
doi: 10.1016/j.bbmt.2019.08.025
Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, et al. Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv. 2020;4:3169–79.
doi: 10.1182/bloodadvances.2020002007
pubmed: 32658984
pmcid: 7362379
Sugihara Y, Hiraoka S, Fujii N, Takashima S, Yamasaki Y, Inokuchi T, et al. Villous atrophy in the terminal ileum is a specific endoscopic finding correlated with histological evidence and poor prognosis in acute graft-versus-host disease after allo-hematopoietic stem cell transplantation. BMC Gastroenterol. 2018;18:111.
doi: 10.1186/s12876-018-0829-4
pubmed: 29996762
pmcid: 6042419
Kreisel W, Dahlberg M, Bertz H, Harder J, Potthoff K, Deibert P, et al. Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transpl. 2012;47:430–8.
doi: 10.1038/bmt.2011.137
Akpek G, Chinratanalab W, Lee LA, Torbenson M, Hallick JP, Anders V, et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transpl. 2003;9:46–51.
doi: 10.1053/bbmt.2003.49999
Gavriilaki E, Sakellari I, Karafoulidou I, Pasteli N, Batsis I, Mallouri D, et al. Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease. Int J Hematol. 2019;110:529–32.
doi: 10.1007/s12185-019-02750-7
pubmed: 31586304
Adler B, Sinzger C. Endothelial cells in human cytomegalovirus infection: one host cell out of many or a crucial target for virus spread? Thromb Haemost. 2009;102:1057–63.
doi: 10.1160/TH09-04-0213
pubmed: 19967135
Ye Y, Zheng W, Wang J, Hu Y, Luo Y, Tan Y, et al. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. Hematol Oncol. 2017;35:821–7.
doi: 10.1002/hon.2310
pubmed: 27245857
Yamamoto S, Nakase H, Chiba T, Yamashita K, Ito M. Clinical challenges and images in GI. Image 4. Transplant-associated thrombotic microangiopathy of the colon accompanied by graft-versus-host disease. Gastroenterology. 2009;136:2067, 2418.
Ramgopal A, Sridar S, Dalal J, Kalpatthi R. Thrombotic microangiopathy: multi-institutional review of pediatric patients who underwent HSCT. J Pers Med. 2021;11:467.
doi: 10.3390/jpm11060467
pubmed: 34070379
pmcid: 8226470